Brands M.M.M.G.,Erasmus Center for Lysosomal and Metabolic Diseases |
Oussoren E.,Erasmus Center for Lysosomal and Metabolic Diseases |
Ruijter G.J.G.,Erasmus Center for Lysosomal and Metabolic Diseases |
Vollebregt A.A.M.,Erasmus Center for Lysosomal and Metabolic Diseases |
And 5 more authors.
Molecular Genetics and Metabolism | Year: 2013
Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI, MPS VI) is a rare progressive metabolic disorder characterized by coarse facial features, hepatosplenomegaly, restrictive pulmonary function, cardiac abnormalities and stiff joints. The disease is caused by a deficiency of the lysosomal enzyme N-acetyl galactosamine 4-sulfatase which leads to glycosaminoglycan (GAG) storage in various tissues. It presents as a clinical spectrum with varying disease progressions and severities. While the phases I/II/III studies proved the effectiveness of enzyme-replacement therapy (ERT) with recombinant human arylsulfatase B, long-term data are still scarce. Over treatment periods ranging from 1.3 to 5.4. years, this prospective open-label follow-up study in 11 Dutch mucopolysaccharidosis type VI patients (age 2-18. years) showed that ERT had significant positive effects on cardiac-wall diameters (IVSd and LVMI), left and right shoulder flexions (p < 0.001), liver size and spleen size (p < 0.001), urinary GAG excretion (p < 0.001), and the scales of quality of life (motor functioning and body functioning). ERT did not affect cardiac valve regurgitation or hearing function; HRQoL decreased slightly in two domains ('anxiety' and 'negative emotions'), and patients with the rapid and slow progressive forms of the disease differed with regard to baseline GAG excretion and GAG decrease during treatment. In conclusion, ERT had an effect on several clinical parameters. This effect was established in an open cohort of young mucopolysaccharidosis type VI patients. © 2013 Elsevier Inc.